期刊文献+

《药物警戒质量管理规范》对我国构建药物警戒制度的意义 被引量:15

Significance of Good Pharmacovigilance Practice in the Construction of China Pharmacovigilance System
下载PDF
导出
摘要 目的探讨《药物警戒质量管理规范》(Good Pharmocovigilance Practice,GVP)对我国建立药物警戒制度的意义。方法回顾GVP出台的背景,研究GVP在药品安全监管领域中地位,概述GVP核心要旨,探讨GVP在我国建立药物警戒制度中的作用。结果和结论GVP的颁布和实施迈出了中国构建药物警戒制度的第一步,对我国全面推进药物警戒制度有着重大意义和深远影响。 Objective To explore the significance of Good Pharmacovigilance Pracetice(GVP)in constructing the Pharmacovigilance System of China.Methods review the background of GVP,study its status in the field of drug safety supervision,summarize its core and gist,discuss its role in the Pharmacovigilance System,and analyze the significance of its introduction.Results and Conclusion the promulgation and implementation of GVP is the first step in the construction of China Pharmacovigilance System,which has great significance and far-reaching influence.
作者 王丹 任经天 吴桂芝 熊玮仪 汤韧 逄瑜 樊蓉 杨乐 WANG Dan;REN Jingtian;WU Guizhi;XIONG Weiyi;TANG Ren;PANG Yu;FAN Rong;YANG Le(Center For Drug Reevaluation,NMPA,Beijing 100022,China)
出处 《中国药物警戒》 2021年第6期501-503,共3页 Chinese Journal of Pharmacovigilance
基金 重大新药创制国家科技重大专项2017年度(2017ZX09101001-001-003)。
关键词 药物警戒 药物警戒制度 药品不良反应监测 药物警戒质量管理规范 pharmacovigilance pharmacovigilance system adverse drug reaction monitoring good pharmacovigilance practice
  • 相关文献

参考文献1

二级参考文献20

  • 1European Commission. The EU pharmacovigilance system[EB/OL]. http://ec.europaeu/health/human-use/pharmacovigilance/index_en. htm#geninf( 2012-09-16 ).
  • 2Peter Arlett. New Pharmacovigilance legislation and focus on post-authorisation studies (2010-11-29)[EB/OL].www.diahome. org/.../24003/session%203_peter%20arlett.pdf (2012-9-16).
  • 3European Medicines Agency. 2010 pharmacovigilance legislation [EB/OL].http://www.ema.europa.eu/ema/index.j sp curl=pages/ regulation/general/general_content_000492.j sp&mid=WC0b01 ac 058033e8ad (2012-9-16).
  • 4European Medicines Agency. Commission Implementing Regula- tion (EU) No 520/2012 (2012-6-19)[EB/OL]. http://eurx.europa. eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025: EN:PDF (2012-9-16).
  • 5European Medicines Agency. Good Pharmacovigilance Practices [ EB/OL ]. http://www, ema. europa, eu/ema/index .j sp curl=pages/ regulation/document_listing/document_listing_000345. j sp&mid=WC0b01 ac058058f32c ( 2012-9-16 ).
  • 6European Medicines Agency. GVP Module I Pharmacovigilance Systems and their Quality Systems (2012-6-22) [EB/OL].http:// www.ema.europa.eu/docs/en_GB/document_library/Scientif- ic_guideline/2012/06/WC500129132.pdf( 2012-09-17 ).
  • 7European Medicines Agency. GVP Module II Pharmacovigilance System Master File(2012-6-22 ) [EB/OL].http://www.ema.europa. eu/docs/en GB/document_library/Scientific_guideline/2012/06/ WCS00129133.pdf(2012-09-17).
  • 8European Medicines Agency. GVP Module III Pharmacovigilance Inspections( 2012-6-22 ) [EB/OL] .http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2012/06/WC500129243. pdf(2012-09-17).
  • 9European Medicines Agency. GVP Module V- Risk Management Systems( 2012-6-22 )[EB/OL].http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2012/06/WC500129134. pdf(2012-9-18).
  • 10European Medicines Agency. GVP Module VI - Management and Reporting of Adverse Reactions to Medicinal Products( 2012-06- 22) [EB/OL].http://www.ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2012/06/WC500129135.pdf( 2012- 09-18).

共引文献22

同被引文献105

引证文献15

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部